Guy's And ST Thomas' NHS Foundation Trust
- Country
- 🇬🇧United Kingdom
- Ownership
- -
- Established
- 1993-01-01
- Employees
- 25
- Market Cap
- -
Clinical Trials
326
Trial Phases
5 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (200 trials with phase data)• Click on a phase to view related trials
Improving Sedation Practice in Critically Ill Adult Patients Using a Co-designed Sedation Protocol
- Conditions
- Intensive Care MedicineRespiratory Distress Syndrome (RDS)Sedation and AnalgesiaExtraCorporeal Membrane Oxygenation (ECMO)Sedation for Mechanical VentilationCardiogenic ShockOpioid AnalgesiaAnalgesia
- First Posted Date
- 2025-06-24
- Last Posted Date
- 2025-06-24
- Lead Sponsor
- Guy's and St Thomas' NHS Foundation Trust
- Target Recruit Count
- 120
- Registration Number
- NCT07032987
- Locations
- 🇬🇧
Guy's and St Thomas' NHS Foundation Trust, London, United Kingdom
Effects of Vibrating Mesh Nebulisation in Patients with COPD During Non-invasive Ventilation (VMN-NIV)
- Conditions
- COPD (Chronic Obstructive Pulmonary Disease)Non-invasive Ventilation
- First Posted Date
- 2025-03-19
- Last Posted Date
- 2025-03-19
- Lead Sponsor
- Guy's and St Thomas' NHS Foundation Trust
- Target Recruit Count
- 12
- Registration Number
- NCT06884228
- Locations
- 🇬🇧
Lane Fox Unit, St Thomas' Hospital, Guy's and St Thomas' NHS Foundation Trust, London, United Kingdom
Effects of Vibrating Mesh Nebulisation in Patients on Long-term Tracheostomy Ventilation: a Pilot Randomised Crossover Trial
- Conditions
- Long-term Tracheostomy Ventilated Patients
- First Posted Date
- 2025-02-19
- Last Posted Date
- 2025-03-03
- Lead Sponsor
- Guy's and St Thomas' NHS Foundation Trust
- Target Recruit Count
- 12
- Registration Number
- NCT06834581
- Locations
- 🇬🇧
Lane Fox Unit, St Thomas' Hospital, London, United Kingdom
Ultrasound Prediction of Successful Balloon Assisted AVF Maturation
- Conditions
- End Stage Renal Disease (ESRD)Chronic Kidney Disease Requiring Hemodialysis
- First Posted Date
- 2025-01-13
- Last Posted Date
- 2025-01-15
- Lead Sponsor
- Guy's and St Thomas' NHS Foundation Trust
- Target Recruit Count
- 40
- Registration Number
- NCT06771973
Assessing the Efficacy of Photodynamic Therapy for Preventing Surgical Site Infections
- Conditions
- SurgeryNasal DiseaseLight; Therapy, Complications
- First Posted Date
- 2024-12-13
- Last Posted Date
- 2025-06-15
- Lead Sponsor
- Guy's and St Thomas' NHS Foundation Trust
- Target Recruit Count
- 80
- Registration Number
- NCT06731881
- Locations
- 🇬🇧
Guy's Hospital, London, United Kingdom
- Prev
- 1
- 2
- 3
- 4
- 5
- 53
- Next
News
Brainomix's e-Lung AI Technology Validated for Progressive Pulmonary Fibrosis Detection in Boehringer Ingelheim Collaboration
New studies presented at the American Thoracic Society Conference validate Brainomix's FDA-cleared e-Lung technology as a reliable tool for identifying progressive pulmonary fibrosis with greater sensitivity than conventional methods.
New Bone Marrow Test Could Double Survival Rates for Acute Myeloid Leukemia Patients
A groundbreaking UK trial has developed a highly sensitive bone marrow test that can detect returning Acute Myeloid Leukemia up to three months earlier than standard blood tests, potentially doubling survival rates for some patients.
JAK Inhibitors Reduce Thromboembolic Risk in Myeloproliferative Neoplasms Through Novel Mechanisms
A meta-analysis of 23 publications involving 2,198 patients demonstrated that JAK inhibitors significantly reduce thromboembolic events by 48% in myeloproliferative neoplasm patients, with ruxolitinib showing a 59% reduction in polycythemia vera and myelofibrosis.
Pembrolizumab Shows Promise in Advanced Clear Cell Gynecologic Cancer, PEACOCC Trial Reports
Phase 2 PEACOCC trial demonstrates pembrolizumab's efficacy with 42% disease control rate at 12 weeks in previously treated advanced clear cell gynecologic cancer patients.
Avapritinib Approved for Advanced Systemic Mastocytosis, Offering New Hope to Patients
Avapritinib, a novel drug, has been approved for treating advanced systemic mastocytosis (ASM) by the UK's NICE.